Frequency and circumstances of placebo use in clinical practice - a systematic review of empirical studies by Fässler, Margrit et al.
RESEARCH ARTICLE Open Access
Frequency and circumstances of placebo use
in clinical practice - a systematic review
of empirical studies
Margrit Fässler
1*, Karin Meissner
2,3, Antonius Schneider
3, Klaus Linde
3*
Abstract
Background: The use of placebo interventions outside clinical trials is ethically, professionally and legally
controversial. Little is known about the frequency and circumstances of placebo use in clinical practice. Our aim
was to summarize the available empirical studies addressing these issues.
Methods: We searched PubMed and EMBASE from inception to July 2009 in order to identify cross-sectional
surveys, qualitative or longitudinal studies among health care professionals, students or patients which investigated
at least one of the following issues - frequency of placebo use or attitudes to, or motivations for, the use of
placebo interventions. At least two reviewers extracted information on the study methods, participants and
findings. Descriptive summaries were prepared in an iterative process by at least two reviewers per study.
Results: Twenty-two studies from 12 different countries met the inclusion criteria. Most studies had relevant
shortcomings. The proportion of respondents reporting that they had applied ‘pure’ placebos (for example, saline
injection) during their professional life varied between 17% and 80% among physicians and between 51% and
100% among nurses, but it seems that the actual frequency of such use seems to be rare. The use of ‘impure’ or
‘active’ placebos (for example, antibiotics for viral infections) is likely to be much more frequent. However, it is
impossible to make a reliable estimation because there is no agreement of what an impure placebo might be.
Studies using qualitative methods or asking participants to judge case examples suggest that motivations and
attitudes towards placebo use are complex and health care providers are often faced with a dilemma.
Conclusions: Although the available evidence is incomplete and confusing at times there can be little doubt that
the prevalence of placebo use outside of clinical trials is not negligible and that views and attitudes on placebos
use differ considerably among individuals, both health care professionals and patients. Further research is needed
to clarify these issues.
Background
Placebos are crucially important for the evaluation of
health care interventions but they are also used in clini-
cal practice. There are many definitions of placebos [1]
and the overall concept is problematic [2-4]. However,
in general, placebos are thought to be interventions
which do not contain components that will improve the
condition being treated. Inert interventions such as
‘sugar pills’ or saline injections are often designated
‘pure’ placebos, whereas therapies that contain active
components, but are considered ineffective for the con-
dition being treated, are called ‘impure’ placebos (for
example, antibiotics in viral infections) [5]. The use of
placebo interventions in clinical practice is ethically,
professionally and legally controversial [6-8] and it is
important that the frequency and the circumstances in
which placebos are used outside clinical trials should be
investigated. Our aim was to systematically summarize
the available empirical data on: the use of placebos in
clinical practice; the respective motivations; and the atti-
tudes of health care professionals, students and patients
towards their use.
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Data sources and searches
The basic requirements of the literature search - inclu-
sion criteria, selection process and extraction - were
specified in advance in a short protocol which can be
obtained from the authors. Potentially relevant articles
were searched in PubMed (from 1966 to July 2009) and
EMBASE (from 1974 to July 2009) and by citation track-
ing. We identified relevant studies using combinations
of words used in the titles (for example, “medical prac-
tice”, “placebo”, “placebo therapy”, “survey”, “use of pla-
cebo”) and/or controlled terms (such as, “attitude”,
“attitude of health personnel, health knowledge, atti-
tudes”, “practice”, “patient care”, “interview”, “medical
practice”, “physician-patient relations”, “placebos”, “pla-
cebo effect”, “questionnaires”).
Selection criteria
In order to be included articles had to meet the follow-
ing criteria: (1) they had to be original reports of cross-
sectional surveys, qualitative studies or longitudinal stu-
dies; (2) participants had to be health care professionals,
students, or patients; and (3) studies had to investigate
at least one of the following issues: frequency of the use
of placebo interventions, attitudes to or motivations for
the use of placebo interventions outside the setting of
clinical trials. We did not have ap r i o r irestrictions
regarding language or publication type, but our search
only identified full-length articles in English and Ger-
man. One reviewer (MF) screened all the hits of the
electronic search and excluded those which were clearly
irrelevant. All reviewers checked their own extensive
files of papers on placebo and the reference lists of
included studies for further potentially relevant publica-
tions. All those papers which were considered poten-
tially relevant were read in full text by three reviewers
and independently assessed for eligibility. Initial dis-
agreements occurred on three studies which were
resolved by discussion.
Data extraction, data synthesis and quality assessment
Due to the great variability of included studies, the
extraction and summarizing of relevant information was
done in an iterative process. As a first step three
reviewers independently extracted the basic information
regarding: the topics addressed; the methodological
approach; sampling; response rates; participants;
whether or not the original questions were available; the
definitions of placebos provided; and whether pure and
impure placebos were separated or whether there was a
focus on one or both of these types of placebos. In the
second step at least two reviewers independently
extracted the results. Thirdly, based on these
extractions, one reviewer compiled tables which sum-
marized the findings of each study regarding the fre-
quency of placebo use, conditions or reasons of placebo
use, use of placebo for separating organic and functional
diseases and personality issues, beliefs in the effective-
ness and ethical issues. Study findings which could not
be summarized reasonably in the table format were
summarized separately. The summary tables and the
separate summaries were read by two other reviewers
and potential improvements to the format were dis-
cussed. In the fourth step, a second reviewer re-
extracted all trials in the same table format. The fifth
step involved the comparison of the summaries and the
final version was established.
As quality indicators for questionnaire-based quantita-
tive surveys at least two reviewers assessed the sampling
method and documented the response rate. Samples
were classified as ‘convenience’ (for example, question-
naires distributed at a conference or in a hospital),
‘local’ (more systematic full or random samples based
on local structures) or ‘random’ (random samples of
clearly defined national or larger regional populations).
For the qualitative studies, we documented whether sys-
tematic sampling, data collection or analytical methods
were used and described.
Results
General overview and methodological quality of
included studies
The literature search identified a total of 3421 references
(see Figure 1). Twenty-nine publications were formally
assessed for eligibility. Four were not original studies
[9-12] and two only addressed issues that were indirectly
related to placebo [13,14]. A total of 22 studies pub-
lished in 23 articles between 1973 and 2009 [15-37] met
the inclusion criteria (see Table 1 and Additional File 1).
Twenty were quantitative surveys in which a total of 29
samples of individuals were asked to answer question-
naires (19 studies), or were interviewed using a highly
structured questionnaire (one study [29], and subgroups
of participants in two [20,22]). Sixteen samples com-
prised physicians, nine comprised nurses, three com-
prised patients and one study included medical interns
or medical students. Most surveys had important short-
comings. We classified three samples as random, six as
local and 20 as convenience samples. Response rates
ranged from 48% to 65% among random samples, from
36% to 94% among local and from 48% to 100% among
convenience samples (seven studies using convenience
sampling did not report on response rates). Two of the
studies reporting questionnaire-based surveys addition-
ally included prospective substudies in which records of
hospital patients were regularly screened for placebo use
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First author year from N Participants Sampling Response
rate
Focus pure/
impure placebo
Questionnaire-based quantitative surveys
Shapiro 1973 [15,16] USA 195 Ph (various groups) Convenience 83% Both
Goldberg 1979 [18] USA 102 N (head nurses at 11 hospitals) Local 68% Pure
Goodwin 1979 [19] USA 60 Ph (house officers) Convenience 100% Mainly
39 N (hospital nurses) Convenience Unclear pure
27 License practical nurses/medical
aides
Convenience Unclear
Gray 1981 [20] CAN 70 Ph (university hospital) Convenience 82%* Pure
230 N (university hospital) Convenience
35 N (experienced hospital nurses) Convenience Unclear
Lange 1981 [21] GER 81 Ph, N, psychologists (no data for
subgroups provided)
Convenience Unclear Pure
Thomson 1982 [22] NZ 37 Ph (GPs) Local 84% Both
Classen 1985 [23] GER 101 Ph (setting unclear) Convenience Unclear Both
Saupe 1986 [24] GER 56 N (at a psychiatric university
hospital)
Convenience 80% Mainly pure
Lynöe 1993 [26] SWE 94 Ph (GPs or affiliated with university) Local 94% Mainly
83 Pt (consecutive patients of three
GPs)
Local 83% impure
Ernst 1997 [27] AUS 263 N (setting unclear) Convenience 58% Both
Berger 1999 [28] USA 74 Medical interns at an university-
affiliated hospital
Convenience 83% Pure
Berthelot 2001 [29] FRA 300 Pt (at a hospital rheumatology
department)
Convenience Unclear Mainly
100 N (same hospital, various
departments)
Convenience Unclear pure
Hrobjartsson 2003 [30] DEN 502 Ph (GPs, hospital, specialists in
private practice)
Random 65% Both
Nitzan 2005 [31] ISR 31 Ph (senior hospital physicians) Convenience 76% Mainly
31 N (head nurses from same
hospitals)
Convenience 100% pure
27 Ph (family physicians) Convenience 68%
Lim 2007 [32] SIN 402 Medical students Local 36% Pure
Sherman 2007 [33] USA 231 Ph (faculty members of 3 medical
schools)
Local 50% Both
Tilburt 2008 [34] USA 679 Ph (internists and rheumatologists) Random 57% Both
Bernateck 2009 [35] GER 71 Ph (university hospital) Convenience 80%* Pure
107 N (university hospital) Convenience
Chen 2009 [36] NZ 211 Pt (in waiting rooms of two GP
clinics)
Convenience 48% Mainly pure
Fässler 2009 [37] SWI 233 Ph (primary care) Random 48% Both
Substudies with prospective screening of
medical records of hospital patients
Goodwin 1979 [19] USA 1900 Pt (academic teaching hospital,
treated during 6 months)
n.a. Pure
Lange 1981 [21] GER 1725 Pt (psychiatric hospital, all treated
1978)
n.a. Pure
Qualitative studies
Comaroff 1976 [17] UK 47 Ph (GPs) Local 92% Mainly impure
Schwartz 1989 [25] USA 72 Ph (selected for often prescribing
inefficient drugs)
n.a. 51% Impure
*Response rate only reported for pooled groups.
Ph = physicians; N = nurses; Pt = patients; GPs = general practitioners; n.a. = not applicable.
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reported qualitative studies in which physicians had
been interviewed [17,25]. Both described sampling
methods but only one [25] provided details on data col-
lection and analysis methods.
Definitions of placebo
Definitions of placebo in the studies varied considerably
(Additional File 2). Six studies did not address defini-
tional issues in the publication and probably in the
questionnaire but five of these clearly focused on pure
placebos [18-21,31], while some of the questions in one
survey also addressed impure placebos [27]. Nine studies
included explicit definitions or explanations in question-
naires or interviews for clarification [23,28-30,32,34-37].
One of these explicitly asked participants not to proceed
with the questionnaire if they disagreed with the defini-
tion [30]. Three studies made the definitional aspects a
topic of the questionnaire. Fässler et al. [37] had pro-
vided definitions for pure and impure placebos but gave
participants the option to rate examples provided as ‘...is
not a placebo intervention’. This option was chosen by
2% to 32% of the respondents. Sherman et al. [33] asked
participants to choose between several definitions (see
Additional File 2 for responses). Shapiro [15,16] listed
21 examples of interventions and a formal definition
and asked participants to rate the degree of their
agreement on whether these interventions should be
considered placebos. Apart from four examples related
to inert drugs, the agreement was less than 70% for all
other listed interventions (see Additional File 2 for
examples). The remaining four studies [17,22,25,26]
addressed their topic indirectly (with case vignettes and
resulting behaviour or through addressing non-scientific
drug prescribing) and bypassed the definitional issues.
Frequency of placebo use
The proportion of physicians who reported having used
placebo (ever used or used with a minimum frequency
of once a year) varied between: 17% and 80% for pure
placebos (six studies); between 54% and 57% for impure
placebos (two studies); and between 41% and 99% if
both pure and impure placebos were addressed (five
groups of physicians in three studies; see Table 2). The
pure placebos mentioned were typically saline injections,
sugar pills or prepared placebo tablets. Typical impure
placebos mentioned included antibiotics for viral infec-
tions, vitamins and analgesics for unproven indications.
However, in studies offering these options, more than
half of respondents also reported the use of non-essen-
tial diagnostic interventions [37] and not specifically
indicated physiotherapy [30]. The use of impure place-
bos seems to be more prevalent in primary care set-
tings; pure placebos seem to be used more frequently in
29 potentially relevant 
publications formally 
assessed for eligibility 
3421 references identified 
and screened 
- 3419 from electronic  
   database search 
- 2 by citation tracking
3392 excluded as inclusion 
criteria clearly not met 
(screening of titles and 
abstracts) 
23 publications included 
reporting 22 studies
6 not meeting inclusion criteria 
- 4 not original studies 
- 2 did not investigate predefined topics 
Figure 1 Study flow diagram.
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Page 4 of 10hospital settings. The reported frequency of placebo was
less than once a month in the majority of the studies
which reported this information but findings were
highly variable depending on the placebo definition
used and the sampling frame. The proportion of hospi-
tal nurses reporting use of (mainly pure) placebos (51%
to 100% in eight studies) was higher than in surveys of
physicians, but the actual frequency of placebo applica-
tions was low. The only study of interns found that 16%
had witnessed the application of a pure placebo; 2% (1
of 47) had actually given a placebo. In the two studies,
based on the review of the medical records of hospital
inpatients, the incidence of the application of pure pla-
cebos (mostly single applications) was 0.3% during 6
months (various departments in a USA hospital) [19]
and 5.1% during 12 months (a psychiatric hospital in
Germany) [21].
Indications and reasons for placebo use, placebo
personality and beliefs in placebo effectiveness
The conditions for which placebos were used and the
reasons for use were not clearly separated in some stu-
dies. Therefore, they are summarized together (Table 3).
Typical indications reported for the use of pure place-
bos, particularly in hospital settings, were pain, insom-
nia, anxiety and risk of substance abuse. A consistent
finding was that patients who were considered as more
difficult or demanding were more likely to receive a
pure placebo. In primary care settings physicians
reported the desire of patients to receive a prescription
as a primary motivation for the use of (particularly,
impure) placebos. Other reasons often reported were to
take advantage of the placebo effect, to avoid conflicts
with patients, as supplemental treatment or for non-spe-
cific symptoms and to avoid telling patients that treat-
ment possibilities were exhausted. The proportion of
physicians and nurses having used (pure) placebos for
diagnostic purposes or who believed that it is possible
to differentiate organic and functional disease varied
greatly between studies (between 4% and 70%; see Addi-
tional File 3). More recent studies reported lower rates
(between 4% and 29%) and nurses tended to report
higher rates than physicians. Seven studies included one
or more questions on whether a variety of factors might
predict placebo response (Additional File 3). Findings
suggest that the majority of physicians, nurses and
patients believe that personality elements are associated
with the likelihood of a patient responding to placebo.
Physicians tended to think that other physicians, or
other specialities than their own, make more use of pla-
cebo (six studies). Questions regarding beliefs in the
effectiveness of placebo applications varied greatly
(Additional File 4). Up to 50% of physicians and nurses
(range 16% to 50%) believed that placebo treatments are
either always, often, or generally effective. Similarly, the
perceived percentage of patients responding to placebo
treatments ranged between 5% and 42%. In the prospec-
tive study of psychiatric patients 45% of the placebo
administrations were rated as successful [21]. Between
25% and 33% of doctors and medical students believed
that placebo treatments can induce not only subjective/
psychological, but also objective or physiological
changes. The two surveys in patients addressing the
issue [29,36] suggest that patients are slightly more
sceptical about placebo effectiveness than physicians and
nurses.
Ethical aspects
Only a small minority of the physicians and nurses par-
ticipating in the included studies thought that the use of
placebos should be categorically prohibited or consid-
ered it should never be permissible (see Additional File
5). At the same time the findings show that the majority
considered the use of placebos as problematic. For
example, in one study 73% reported that placebo use
means deceiving the patient [27] and, in another survey,
45% agreed to the statement that placebo use must be
rejected as it implies deception [37]. A minority of phy-
sicians seems to have no, or only a few, reservations to
the use of placebo. The surveys of patients indicate that
opinions on whether placebo application is appropriate
are highly divergent and strongly dependent on the spe-
cific situation [26,29,38]. If placebos are applied for the
benefit of the patient, up to 50% or even more consider
it acceptable.
Narrative summary of studies not fitting into the
extraction format
Three studies did not fit into our formal extraction
scheme and are summarized narratively. In the study by
Lynöe et al. [26] 83 patients and 94 physicians were
given the same questionnaire which described three
hypothetical cases and then asked to judge the situations
and actions (see Additional File 6). The results showed
that judgements about the acceptability of a defined
action depended on specific situations and varied
strongly both between and within the patients group
and the physicians group. In general, there was tension
between the physicians’ respect for the patients’ wishes
and the patients’ respect for the physician’s professional
autonomy. For example, 65% of patients and 30% of
physicians agreed that physicians ought to oblige a
patient’s desire even if they consider a treatment to be a
placebo, while 60% and 87%, respectively, agreed that
patients ought to respect a physician’s refusal to give a
treatment she/he considers to be a placebo.
In a qualitative study addressing placebo use indirectly
Comaroff [17] interviewed 47 general practitioners
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Author year Setting Type Placebo
use
Definition of use Frequency or other additional
information
Questionnaire- based quantitative
surveys
Physicians
Goodwin 1979 [19] Hospital
(house
officers)
Pure* 78% Ever use for pain relief
Gray 1981 [20] Hospital Pure 80% Ever use
Classen 1985 [23] Unclear Pure 60% Use ‘sometimes’ About 30% less than once a month
Classen 1985 [23] Unclear Impure 54% Use ‘sometimes’
Lynöe 1993 [26] Unclear Both 99% Ever use None very often, 1% often, 4% rather often,
26% quite rarely, 68% rarely/very rarely
Hrobjartsson 2003 [30] General
practice
Both 86% During the last year 38% 1-10 times/year, 48% > 10 times/year
Hrobjartsson 2003 [30] Hospital Both 54% During the last year 44% 1-10 times/year, 10% > 10 times/year
Hrobjartsson 2003 [30] Specialist
practice
Both 41% During the last year 31% 1-10 times/year, 10% > 10 times/year
Nitzan 2004 [31] Hospital/
family
practice
Pure* 53% Use with a minimum
frequency of once a
year
37% once a month or more often†
Sherman 2007 [33] Medical
school
faculty
Both 45% Ever use 15% 1-10×, 8% > 10×, 22% not at all
during last year
Tilburt 2008 [34] Specialist
practice
Both 80% Ever use 34% = once a month, 28% 2-3 times/
month, 18% = once a week
Bernateck 2009 [35] Hospital Pure 52% Use with a minimum
frequency of once a
year
40% 1-2 times/year, 9% 1-2 times/month,
4% more often
Fässler 2009 [37] Primary care Pure 17% Ever use 93% once a month or less often
Fässler 2009 [37] Primary care Impure 57% Ever use
Nurses
Goldberg 1979 [18] Hospital Pure 51% Ever use 44% with current use or use in the last 6
months
Goodwin 1979 [19] Hospital Pure* 82% Ever use for pain relief
Gray 1981 (sample 1) [20] Hospital Pure 80% Ever use
Gray 1981 (sample 2) [20] Hospital Pure 89% At least once during the
last 5 years
63% during the last year
Saupe 1985 [24] Hospital Pure 100% Ever use 79% once or less per month, 21% more
often
Ernst 1997 [27] Unclear Pure 57% Ever use
Ernst 1997 [27] Unclear Both 68% Ever use 12% during the last year
Nitzan 2004 [31] Hospital Pure* 71% Use with a minimum
frequency of once a
year
37% once a month or more often†
Bernateck 2009 [35] Hospital Pure 87% Use with a minimum
frequency of once a
year
45% 1-2 times/year, 33% 1-2 times/month,
9% more often
Interns
Berger 1999 [28] Hospital Pure 16% Ever witnessed use Only 2% (1/47) had actually given a
placebo
Substudies with prospective screening of
medical records of hospital patients
Goodwin 1979 [19] Hospital Pure* 0.3% During 6 months
(prospective)
Lange 1981 [21] Psychiatric
hospital
Pure 5.1% During 12 months
(prospective)
6.1% in women, 3.9% in men
* Limitation to pure placebo not explicitly stated but questions/report with clear focus on pure placebo use.
† Numbers related to both physicians and nurses.
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Page 6 of 10(GPs) in Wales. She first asked physicians to estimate
the proportion of consultations that culminated in a
prescription. In the majority of cases this induced a dis-
cussion on the adequacy of high prescription rates and
only partly on the placebo effect. The emerging pattern
of responses showed that GPs shared the strong implicit
professional ideal that treatment should always be speci-
fic and prescribed only when necessary. However, this
ideal conflicted with the uncertainty and ambiguity in
many situations in general practice. One of the options
to prevent a possibly unsettling hesitation was the use
of therapies which, according to scientific theory, are
not or not fully indicated. The GPs justified this
inadequate use - according to professional standards -
by stating that they were satisfying the patient’s expecta-
tions. Other important justifications were the beneficial
effects associated with any therapy or with some sort of
faith in the specific effects of the therapy despite con-
flicting external evidence. Placebo therapy or unscienti-
fic prescribing also seemed to serve a need to give the
patient the feeling of being cared for in spite of the lack
of time that GPs were allowed to give at any one
appointment.
Schwartz et al. [25] interviewed, in a standardized
manner, 72 physicians who had been identified from a
Medicaid database as prescribing drugs of doubtful
Table 3 Summary of findings regarding conditions in which placebos are used and/or reasons for using placebos.
First author year Indications/reasons
Goldberg 1979 [18] N: In 39 of 43 (91%) patient’s pain was an indication. For 36 patients more than one reason was reported; in 51% anxiety;
in 47% symptoms suspected not to be organic; in 33% in suspected drug abuse; in 24% as nothing else was helping; in
16% fear of iatrogenic addiction; in 7% concern for patient safety; in 37 of 43 patients receiving placebo (86%) anxiety and
emotional problems were seen as prominent; 28% were considered less likeable; 30% more difficult than average; 81%
were considered questionable or unreliable.
Goodwin 1999 [19] Ph/N: 87% of physicians and 97% of registered nurses who had used a placebo in the past had ordered it for a patient
requiring more pain medication that thought necessary; 74% and 84% had ordered it in ‘problem patients’
Gray 1981 [20] Ph/N: Conditions: 89% pain (45% patients with regular narcotic analgesia; 34% postoperative; 8% terminally ill); 9% anxiety.
More than half of replies indicated that patients describing features such as manipulative, complaining, and histrionic
behaviour usually received placebos.
Lange 1981 [21] Diagnoses in the 88 patients receiving placebo from the 1725 psychiatric patients surveyed: 27% schizophrenia and
paranoid symptoms; 27% abuse; 19% depressive psychoses; 14% hysteric syndromes. Symptoms treated with placebo: 40%
pain; 29% sleep problems; 8% agitation. Reasons for placebo application: most frequently to cope with a difficult situation
and in frequently complaining or disliked patients. Further reasons: other interventions not successful; avoid substance
abuse; patients desire for receiving drug treatment.
Classen 1985 [23] Ph: In patients who demand too many, too powerful or inadequate drugs (50%); psychosomatic complaints (42%); pain
(36%); somatic disorders (7%).
Saupe1986 [24] N: 72% in demanding patients; 78% in patients with so called psychosomatic complaints; 67% requests for pain relief.
Ernst 1997 [27] N: Probably open-ended question (responses given by placebo users): 19% pain; 11% insomnia; 7% both; 8% anxiety; 5%
addiction.
Berger 1999 [28] Medical interns: Likely to use a placebo in the following circumstances: Suspicion of factitious pain (48%); history of
substance abuse (18%); psychiatric illness/psychological component (17%).
Hrobjartsson 2003 [30] Ph: 226 (45%) respondents provided examples: 90 used various placebos as for treating pain; 86 antibiotics for viral
infections; 32 vitamins against fatigue; 28 various placebos for cough and chronic obstructive lung disease. Reported
reasons (total sample): follow the wish of the patient and avoid conflicts with patients (70% GPs, 46% hospital clinicians,
42% private specialists); take advantage of the placebo effect (48%, 22%, 32%); avoid discontinuation of other prescriptions
(40%, 27%, 18%); avoid telling patients that treatment possibilities are exhausted (36%, 11%, 17%).
Nitzan 2004 [31] Ph/N: Conditions: The medical conditions for which the placebos were used included anxiety, pain (including abdominal),
agitation, vertigo, sleep problems, asthma, contractions in labour, withdrawal from recreational drugs, and angina pectoris
(when the blood pressure was too low to allow for vasodilators). Reasons: 43% after ‘unjustified’ demand of medication;
38% to calm the patient; 38% as analgesic; 28% as diagnostic tool; 23% as adjunctive therapy; 17% for non-specific
complaints; 15% to buy time before next regular dosage of medication; 11% to get patient to stop complaining.
Sherman 2007 [33] Ph: Among placebo users 18% used placebos to calm the patient; 18% as supplemental treatment; 15% after ‘unjustified’
demand for medication; 13% for non-specific symptoms; 11% after all treatment possibility were exhausted; 6% to control
pain; 6% to get the patient stop complaining.
Bernateck 2009 [35] Ph: Conditions (responses given by placebo users): 76% (65% physicians, 81% nurses) for pain; 59% insomnia (40%, 66%);
12% depressive mood (19%, 10%). Reasons for placebo application: 64% (57%, 66%) patient’s request for a drug; 37% (35%,
38%) for calming an anxious patient; 35% (24%, 40%) for reducing drug use; 20% (30%, 16%) for supporting other
interventions; 18% (24%, 16%) to treat non-specific symptoms.
Fässler 2009 [37] Ph: 69% of placebo users report as motive ‘to gain therapeutic advantage through the placebo effect’; 64% ‘to offer a
treatment to patients whose complaints and test results are not attributable to a certain disease’; 63% ‘to conform with
the requests of the patient’; 51% ‘to offer treatment to difficult patients’; 44% ‘to offer a treatment option to a patient with
an incurable disease’; 37% ‘in situations in which standard treatments may burden patients with side effects or are
contraindicated’; 31% ‘to avoid drug addiction’.
Ph = physicians; N = nurses; GP = general practitioner.
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results described by Comaroff [17], they found that the
most frequent justification (51 from a total of 110 rea-
sons provided) was patient demand, often combined
with the fear of losing patients. A distinct subgroup of
physicians considered their positive personal experience
with the drugs prescribed as being more important and
valid than scientific studies (26% of statements). In 24%
of responses the placebo effect was reported as a reason.
Discussion
Summary of main findings
The results of the available surveys show that a signifi-
cant proportion of physicians and nurses have applied
‘pure’ placebos (such as saline injection or sugar pills)
during their professional life, but the actual frequency of
such use seems to be rare except for a small minority of
frequent users. The use of ‘impure’ or ‘active’ placebos
(for example, antibiotics for viral infections) is likely to
be much more frequent but, due to the lack of agree-
ment on what actually has to be considered an impure
placebo and to the unclear influence of the social desir-
ability of placebo, when health care professionals are
asked to admit its use it is not always possible to pro-
duce reliable estimations. In particular, the studies using
qualitative methods, or asking participants to judge case
vignettes, show that motivations and attitudes towards
placebo use are complex, and often cause a dilemma for
health care providers. In this situation quantitative sur-
veys might miss many relevant issues.
Strengths and limitations
To the best of our knowledge this is the first systematic
review which summarizes the available empirical data
on the actual use of placebos in clinical practice and the
related attitudes and beliefs. As our predefined selection
criteria were wide, our study set is highly heterogeneous
regarding the design, samples, quality and topics
addressed. We consider it to be a strength of our review
that it provides the overall picture. This shows that the
available evidence is disparate, which points to the enor-
mous complexity of the issue. We were fascinated by
the multiple facets of the placebo problem detected in
our study sample exactly because of its heterogeneity.
However, for the process of a systematic review such
heterogeneity is associated with drawbacks. The metho-
dological quality of the included studies could only be
assessed in a basic manner. Nevertheless, it is obvious
that most studies had relevant shortcomings. For exam-
ple, the reported frequencies of placebo use might be
biased by the use of convenience sampling or low
response rates - or both. Our attempt to cover a broad
variety of aspects made it difficult to summarize the
results of primary studies in a transparent manner.
Therefore, we provide detailed tables that allow the
reader to check our narrative summaries and to see
which numbers refer to which study. Due to the metho-
dological shortcomings and the heterogeneity of the pri-
mary studies there is room for interpretation.
Interpretation
There is broad consensus that interventions such as saline
injections for pain or sugar pills are (pure) placebos. The
application of such pure placebos can be characterized
relatively easily: the provider is aware and convinced that
he is applying something which has no direct, specific or
physiological effect. The application is almost always
deceptive, in the sense that the patient is not informed of
the provider’s view and, if fully informed, the patient also
would probably consider the intervention to be a placebo.
P u r ep l a c e b o sa r em a i n l yu s e da ss i n g l eo rs h o r t - t e r m
applications and, typically, in situations which are difficult
for some reason. Many of the reasons for applying pure
placebos seem to be ethically and professionally difficult,
such as the use in patients who are demanding too much
medication. However, there are also many situations
where the compromise between helping and deceiving the
patient is much more difficult. The advantage of pure pla-
cebos compared to impure placebos is that there is no
direct toxicity (although nocebo effects - negative effects
associated with the application of an inert intervention -
can occur [39]). Therefore, doing no harm is an often
reported reason in cases when pure placebos are used.
There seems to be a small minority of physicians who
make frequent use of pure placebos. It would seem worth-
while to investigate the motivations of these physicians.
The available data suggests that, in hospitals, nurses tend
to use (pure) placebos more frequently than physicians.
This finding could be due to the fact that each nurse
receives orders from several physicians. A further explana-
tion could be that nurses more often have to deal with dif-
ficult situations when caring for patients the care or that
the closer nurse-patient interaction in many hospitals
accounts for this difference. The few available surveys of
patients suggest that placebo application seems to be
acceptable to many in certain situations.
Interpreting the available data on the use of impure
placebos is difficult. What is considered to be an impure
placebo varies considerably among studies and it is
unclear and subjective when an intervention is a placebo
or an active or effective intervention. Surveys investigat-
ing definitional aspects reveal considerable disagreement
regarding whether defined interventions should be con-
sidered (impure) placebos or not [16,37]. Context and
motivations for using impure placebos seem to be vari-
able and often different than for pure placebos. With
this lack of clarity it is doubtful whether the evaluation
of something such as ‘the prevalence of the use of
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more on how questions are posed than on what partici-
pants actually think. For example, some of the authors
of responses http://www.bmj.com/cgi/eletters/337/
oct23_2/a1938 to the recent study by Tilburt et al.[ 3 4 ]
believe that the comparably high rates of ‘placebo’ use
in this survey are due to the specific wording of the
relevant question which may result in physicians classi-
fying interventions as placebo treatment when they nor-
mally would not consider them to be placebos. In
qualitative studies addressing the prescription of antibio-
tics for sore throats physicians tend to acknowledge that
they are well aware that their behaviour is problematic
but the word placebo does not seem to come up
[38,40]. The academic concept of an impure placebo
might inappropriately reflect the complex situations and
motivations in which health care professionals apply
interventions which are not backed up by scientific
evidence.
Conclusions
Although there is a plethora of review articles and an
increasing number of laboratory and clinical studies
dealing with placebo and placebo effects, empirical
investigations on the current use of placebos in clinical
practice and on the respective attitudes of health care
professionals, students or patients are sparse. While the
available evidence is incomplete and partly confusing
there can be little doubt that (a) the prevalence of the
use of ‘pure’ and ‘impure’ placebos (or scientifically
inadequate interventions) outside clinical trials is not
negligible, and that (b) views and attitudes on placebos
use differ considerably among individuals, both among
health care professionals and patients. Future more care-
fully planned, rigorous, questionnaire-based quantitative
surveys could provide additional information on placebo
use and attitudes. Researchers should consider not only
pilot testing questionnaires among a limited number of
persons but also systematically interviewing participants
of the pilot study to check whether questions have been
really understood in the intended manner. Qualitative
studies investigating in more detail the circumstances
and motivations for placebo use or inadequate prescrib-
ing would be of particular interest. Based on the avail-
able evidence, we addressed the placebo issue almost
exclusively from the perspectives of scientists and health
care providers. Future studies should also investigate the
perspectives of patients.
The authors believe that the use of pure placebos
should be restricted to exceptional situations due to the
deceptive element involved. In some uncertain situations
health care professionals will probably (have to) con-
tinue to use interventions which are considered by
scientists to be impure placebos. Physicians should be
aware that there is a tendency to use problematic ratio-
nales (perceived patient expectations of prescriptions,
unjustified faith in efficacy, using a prescription as a
substitute of time) as legitimization and to repress the
dilemmas associated with uncertainty. Relevant research
on placebo might yield findings that could contribute to
the development of a more honest and efficient patient-
provider relationship.
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